<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 22, 2000
CERUS CORPORATION
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
<TABLE>
<S> <C> <C>
0-21937 68-0262011
(Commission File No.) (IRS Employer Identification No.)
</TABLE>
2525 STANWELL DR., SUITE 300
CONCORD, CALIFORNIA 94520
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (925) 603-9071
------------------------------
<PAGE> 2
ITEM 5. OTHER EVENTS.
On August 22, 2000, Cerus Corporation, with its development partner, Baxter
Healthcare Corporation, announced the results of their European Phase 3 clinical
trial of the Intercept(TM) system to inactivate pathogens in platelets. The
press release announcing the results of the trial is filed as Exhibit 99.1
hereto. The data and results from the trial are filed as Exhibit 99.2 hereto.
ITEM 7. EXHIBITS.
<TABLE>
<S> <C>
99.1 Press Release, dated as of August 22, 2000 entitled "Cerus and Baxter
Announce Results of European Phase 3 Trial of Their Intercept Platelet
System for Pathogen Inactivation"
99.2 Data and Results from European Phase 3 Trial of the Intercept Platelet
System for Pathogen Inactivation
</TABLE>
2
<PAGE> 3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
CERUS CORPORATION
Dated: August 22, 2000 By: /s/ GREGORY W. SCHAFER
----------------------
Gregory W. Schafer
Chief Financial Officer
3
<PAGE> 4
INDEX TO EXHIBITS
<TABLE>
<S> <C>
99.1 Press Release, dated as of August 22, 2000 entitled "Cerus and Baxter
Announce Results of European Phase 3 Trial of Their Intercept Platelet
System for Pathogen Inactivation"
99.2 Data and Results from European Phase 3 Trial of the Intercept Platelet
System for Pathogen Inactivation
</TABLE>
4
